Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Hydroxychloroquine Plus TPO-RA in Antinuclear Antibody-positive Patients With Primary Immune Thrombocytopenia-- The Multicenter, Randomized, Open-labled Clinical Trial

NCT06479291 is registered in ClinicalTrials.gov with Yunfeng Cheng as lead sponsor.

NCT NCT06479291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06479291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Hydroxychloroquine Plus TPO-RA in Antinuclear Antibody-positive Patients With Primary Immune Thrombocytopenia-- The Multicenter, Randomized, Open-labled Clinical Trial
Lead sponsor
Yunfeng Cheng
Phase
Not applicable
Overall status
Recruiting
Start date
July 31, 2024
Completion date
December 31, 2026
Enrollment
126 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia with positive ana antibodies